BridgeBio Pharma, Inc.
BBP-418
LGMD2I/R9
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on BBP-418 for LGMD2I/R9 is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027”